welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
PTC Therapeutics, Inc. today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year’s funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.
“We were overwhelmed to receive so many outstanding applications in the first year of PRIORITY and to see such a breadth of ideas to improve the screening and diagnosis of Duchenne,” said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics, Inc. “We are thrilled that the PRIORITY program will help bring these research projects to fruition and ultimately help patients receive the best care as early as possible.”
rareRelated
-
Therapeutic advances in muscular dystrophyThe muscular dystrophies comprise a hete...
-
Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosageObjective: Development of an accurate a...
-
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular DystrophyThe proposed clinical trial study of rAA...
-
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)The aim of this study is to provide cont...
-
Jacques P. Tremblay, PhDDr. Tremblay’s laboratory is renowned ...
-
Experts review current and potential treatments for Duchenne muscular dystrophyExperts provided an overview of the many...
-
Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging PharmacotherapiesDuchenne muscular dystrophy (DMD) is a g...
